<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Biotechblog</title>
	<atom:link href="http://www.biotechblog.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.biotechblog.com</link>
	<description>Biotechnology business, policy, and more!</description>
	<lastBuildDate>Sun, 06 Sep 2026 10:20:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>
	<item>
		<title>The China Patent Linkage System Changed in Ways Most US IP Teams Haven’t Noticed</title>
		<link>https://www.drugpatentwatch.com/blog/the-china-patent-linkage-system-changed-in-ways-most-us-ip-teams-havent-noticed/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Sun, 06 Sep 2026 10:20:10 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-china-patent-linkage-system-changed-in-ways-most-us-ip-teams-havent-noticed/</guid>

					<description><![CDATA[Most U.S. IP teams track China through the lens of patent linkage being a single, monolithic conceptfile once, then the system plays out predictably. But the reality is less stable than most playbooks assume. Recent changes to Chinas patent linkage sys...
<p><a href="https://www.drugpatentwatch.com/blog/the-china-patent-linkage-system-changed-in-ways-most-us-ip-teams-havent-noticed/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The New Owner Didn’t File the Patent. Here’s Who Actually Controls It.</title>
		<link>https://www.drugpatentwatch.com/blog/the-new-owner-didnt-file-the-patent-heres-who-actually-controls-it/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Sat, 05 Sep 2026 10:36:24 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-new-owner-didnt-file-the-patent-heres-who-actually-controls-it/</guid>

					<description><![CDATA[A drug patent can be owned on paperyet effectively controlled by someone else.
Thats the uncomfortable reality DrugPatentWatch highlights in its latest piece: when a new owner fails to file the patent assignment properly, the chain of control can fract...
<p><a href="https://www.drugpatentwatch.com/blog/the-new-owner-didnt-file-the-patent-heres-who-actually-controls-it/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar</title>
		<link>https://www.drugpatentwatch.com/blog/zero-for-two-why-no-antibody-drug-conjugate-has-ever-faced-a-biosimilar/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Fri, 04 Sep 2026 09:23:15 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/zero-for-two-why-no-antibody-drug-conjugate-has-ever-faced-a-biosimilar/</guid>

					<description><![CDATA[Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar
For investors, the biosimilar story has been one of the most reliable value creation engines in healthcareuntil you look at antibody-drug conjugates.
So far, the scorecard is zero...
<p><a href="https://www.drugpatentwatch.com/blog/zero-for-two-why-no-antibody-drug-conjugate-has-ever-faced-a-biosimilar/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Platform Patents Were Supposed to Protect Gene Editing. Fourteen Years of CRISPR Litigation Say Otherwise.</title>
		<link>https://www.drugpatentwatch.com/blog/platform-patents-were-supposed-to-protect-gene-editing-fourteen-years-of-crispr-litigation-say-otherwise/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Thu, 03 Sep 2026 10:52:23 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/platform-patents-were-supposed-to-protect-gene-editing-fourteen-years-of-crispr-litigation-say-otherwise/</guid>

					<description><![CDATA[CRISPR was supposed to be protected by platform patents. Fourteen years later, the litigation story says: not really.
For years, the gene-editing industry has operated on a kind of legal common sense: broad, platform patents would establish stable grou...
<p><a href="https://www.drugpatentwatch.com/blog/platform-patents-were-supposed-to-protect-gene-editing-fourteen-years-of-crispr-litigation-say-otherwise/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Stop Tracking Drug Patents. Start Tracking Who Controls Them.</title>
		<link>https://www.drugpatentwatch.com/blog/stop-tracking-drug-patents-start-tracking-who-controls-them/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Thu, 03 Sep 2026 10:33:49 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/stop-tracking-drug-patents-start-tracking-who-controls-them/</guid>

					<description><![CDATA[Stop Tracking Drug Patents. Start Tracking Who Controls Them.
Drug patent analytics used to be a clean story: list the patents, map the expirations, forecast generic entry. It was orderlyalmost spreadsheet-predictable. But the market doesnt move in str...
<p><a href="https://www.drugpatentwatch.com/blog/stop-tracking-drug-patents-start-tracking-who-controls-them/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>No AI Has Ever Been Named Inventor on a Drug Patent. Here’s the Rule That Guarantees It.</title>
		<link>https://www.drugpatentwatch.com/blog/no-ai-has-ever-been-named-inventor-on-a-drug-patent-heres-the-rule-that-guarantees-it/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 11:09:13 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/no-ai-has-ever-been-named-inventor-on-a-drug-patent-heres-the-rule-that-guarantees-it/</guid>

					<description><![CDATA[No AI Has Ever Been Named an Inventor on a Drug PatentHeres the Rule That Guarantees It
If youve followed the AI headline cycle lately, youve probably seen the recurring claim: AI will soon be an inventor on patents. It sounds inevitableuntil you look ...
<p><a href="https://www.drugpatentwatch.com/blog/no-ai-has-ever-been-named-inventor-on-a-drug-patent-heres-the-rule-that-guarantees-it/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Google Patents Wasn’t Built for Pharma — Here’s What It Misses Every Time You Search a Drug Name</title>
		<link>https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 10:52:37 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/</guid>

					<description><![CDATA[Google Patents wasnt built for pharma. Heres what it misses every time you search a drug name.
Pharma teams dont Google patentsthey interrogate them.
Yet the moment you type a molecule, a brand name, or an ingredient into Google Patents, youre likely g...
<p><a href="https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Google Patents Wasn’t Built for Pharma — Here’s What It Misses Every Time You Search a Drug Name</title>
		<link>https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Wed, 02 Sep 2026 10:52:37 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/</guid>

					<description><![CDATA[Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.  
But if youre in pharmaregula...
<p><a href="https://www.drugpatentwatch.com/blog/google-patents-wasnt-built-for-pharma-heres-what-it-misses-every-time-you-search-a-drug-name/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Free Patent Database Costing Your Team Thousands an Hour in Manual Cross-Referencing</title>
		<link>https://www.drugpatentwatch.com/blog/the-free-patent-database-costing-your-team-thousands-an-hour-in-manual-cross-referencing/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Tue, 01 Sep 2026 10:15:04 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-free-patent-database-costing-your-team-thousands-an-hour-in-manual-cross-referencing/</guid>

					<description><![CDATA[The Free Patent Database Isnt FreeIts Costing You Thousands an Hour
Theres a special kind of corporate mythology: the idea that if something is free, the work to use it is also free.
Its a comforting beliefuntil you try to use a so-called free patent d...
<p><a href="https://www.drugpatentwatch.com/blog/the-free-patent-database-costing-your-team-thousands-an-hour-in-manual-cross-referencing/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Why a Spreadsheet of Expiration Dates Isn’t a Strategy — It’s a Liability With a Due Date</title>
		<link>https://www.drugpatentwatch.com/blog/why-a-spreadsheet-of-expiration-dates-isnt-a-strategy-its-a-liability-with-a-due-date/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Tue, 01 Sep 2026 10:10:28 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/why-a-spreadsheet-of-expiration-dates-isnt-a-strategy-its-a-liability-with-a-due-date/</guid>

					<description><![CDATA[A spreadsheet of patent expiration dates isnt a strategy. Its a liabilitywith a due date.
Drug developers and strategics teams have been doing it for years: pull the database, sort the expiration calendar, flag the must-win molecules, and assign intern...
<p><a href="https://www.drugpatentwatch.com/blog/why-a-spreadsheet-of-expiration-dates-isnt-a-strategy-its-a-liability-with-a-due-date/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Analyst Report That Took Three Weeks Should Have Taken Three Hours — Here’s the Bottleneck</title>
		<link>https://www.drugpatentwatch.com/blog/the-analyst-report-that-took-three-weeks-should-have-taken-three-hours-heres-the-bottleneck/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Mon, 31 Aug 2026 10:53:56 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-analyst-report-that-took-three-weeks-should-have-taken-three-hours-heres-the-bottleneck/</guid>

					<description><![CDATA[ð¨ The three-week bottleneck isnt a workload problemits a process problem.  
In an era when drug approvals, reimbursement decisions, and competitive launches move at the speed of data, waiting three weeks for an analyst report that should have taken ...
<p><a href="https://www.drugpatentwatch.com/blog/the-analyst-report-that-took-three-weeks-should-have-taken-three-hours-heres-the-bottleneck/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Why “We’ll Catch It in the Quarterly Review” Is How Companies Miss NCE-1 Dates Every Year</title>
		<link>https://www.drugpatentwatch.com/blog/why-well-catch-it-in-the-quarterly-review-is-how-companies-miss-nce-1-dates-every-year/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Mon, 31 Aug 2026 09:26:10 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/why-well-catch-it-in-the-quarterly-review-is-how-companies-miss-nce-1-dates-every-year/</guid>

					<description><![CDATA[Drug patent strategy lives and dies by the calendar. And yet, most companies still treat key NCE milestones like theyre optional.
In a world where one wrong assumption can shift exclusivity by monthsor yearsthis is the most expensive habit in pharma: f...
<p><a href="https://www.drugpatentwatch.com/blog/why-well-catch-it-in-the-quarterly-review-is-how-companies-miss-nce-1-dates-every-year/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Stop Searching Patents. Start Asking Them Questions.</title>
		<link>https://www.drugpatentwatch.com/blog/stop-searching-patents-start-asking-them-questions/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Sun, 30 Aug 2026 10:33:47 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/stop-searching-patents-start-asking-them-questions/</guid>

					<description><![CDATA[Stop Searching Patents. Start Asking Better Questions.
If youve spent any time in life sciences innovation, youve seen the same pattern: someone searches patents to understand a competitive landscape, to assess freedom-to-operate, or to justify a pipel...
<p><a href="https://www.drugpatentwatch.com/blog/stop-searching-patents-start-asking-them-questions/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Your Competitive Intelligence Team Is Still Reading PACER by Hand. Here Is the Cost in Reaction Time.</title>
		<link>https://www.drugpatentwatch.com/blog/your-competitive-intelligence-team-is-still-reading-pacer-by-hand-here-is-the-cost-in-reaction-time/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Sat, 29 Aug 2026 11:11:27 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/your-competitive-intelligence-team-is-still-reading-pacer-by-hand-here-is-the-cost-in-reaction-time/</guid>

					<description><![CDATA[Your competitive intelligence team is still reading PACER by hand. Heres the cost in reaction time.
In the pharma and life sciences world, speed isnt just a nice to have. Its a competitive moat.
If your competitive intelligence team is still pulling do...
<p><a href="https://www.drugpatentwatch.com/blog/your-competitive-intelligence-team-is-still-reading-pacer-by-hand-here-is-the-cost-in-reaction-time/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates</title>
		<link>https://www.drugpatentwatch.com/blog/the-three-clock-problem-why-patent-expiration-dates-dont-predict-generic-launch-dates/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Fri, 28 Aug 2026 10:08:27 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-three-clock-problem-why-patent-expiration-dates-dont-predict-generic-launch-dates/</guid>

					<description><![CDATA[The Three-Clock Problem: Why Patent Expiration Dates Dont Predict Generic Launches
If youve ever tried to map a blockbusters patent expiry to a predictable generic launch window, youve probably felt the same frustration: the calendar says one thing, th...
<p><a href="https://www.drugpatentwatch.com/blog/the-three-clock-problem-why-patent-expiration-dates-dont-predict-generic-launch-dates/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Patent Cliff Is a Myth. What Actually Happens Is a Patent Staircase, and Most Models Miss the Steps</title>
		<link>https://www.drugpatentwatch.com/blog/the-patent-cliff-is-a-myth-what-actually-happens-is-a-patent-staircase-and-most-models-miss-the-steps/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Thu, 27 Aug 2026 09:48:47 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-patent-cliff-is-a-myth-what-actually-happens-is-a-patent-staircase-and-most-models-miss-the-steps/</guid>

					<description><![CDATA[The patent cliff is one of those phrases that refuses to diebecause it sounds dramatic. A blockbuster drugs protections expire, revenues tumble, generics flood in overnight, and shareholders brace for impact.
But the story is often wrong.
A recent anal...
<p><a href="https://www.drugpatentwatch.com/blog/the-patent-cliff-is-a-myth-what-actually-happens-is-a-patent-staircase-and-most-models-miss-the-steps/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Blockbuster’s Real Patent Is the Weak One Nobody Challenged</title>
		<link>https://www.drugpatentwatch.com/blog/the-blockbusters-real-patent-is-the-weak-one-nobody-challenged/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Thu, 27 Aug 2026 09:27:26 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-blockbusters-real-patent-is-the-weak-one-nobody-challenged/</guid>

					<description><![CDATA[The real blockbuster isnt the drugits the weak patent nobody bothered to challenge.
Every pharma story sounds the same on the surface: a new blockbuster launches, a wave of follow-on filings appears, and thenyears latertheres a long-awaited patent chal...
<p><a href="https://www.drugpatentwatch.com/blog/the-blockbusters-real-patent-is-the-weak-one-nobody-challenged/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Strong IP Doesn’t Win in Court. Enforceable IP Does.</title>
		<link>https://www.drugpatentwatch.com/blog/strong-ip-doesnt-win-in-court-enforceable-ip-does/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Wed, 26 Aug 2026 10:24:50 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/strong-ip-doesnt-win-in-court-enforceable-ip-does/</guid>

					<description><![CDATA[Strong IP Doesnt Win in CourtEnforceable IP Does
In pharma, its easy to confuse strength with survivability.
Companies invest years building patent wallslayering claims, stacking continuations, expanding coverage, and betting big on courtroom outcomes....
<p><a href="https://www.drugpatentwatch.com/blog/strong-ip-doesnt-win-in-court-enforceable-ip-does/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>Stop Calling It “Loss of Exclusivity” — For Most Drugs, It’s Loss of Pricing Power, Not Loss of Revenue</title>
		<link>https://www.drugpatentwatch.com/blog/stop-calling-it-loss-of-exclusivity-for-most-drugs-its-loss-of-pricing-power-not-loss-of-revenue/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Tue, 25 Aug 2026 10:47:01 +0000</pubDate>
				<category><![CDATA[General Biotechnology]]></category>
		<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/stop-calling-it-loss-of-exclusivity-for-most-drugs-its-loss-of-pricing-power-not-loss-of-revenue/</guid>

					<description><![CDATA[Stop Calling It Loss of Exclusivity for Most DrugsIts Loss of Pricing Power, Not Revenue
For years, the industry has repeated a soothing phrase: loss of exclusivity. It sounds clinical, inevitable, almost benignlike a patent clock running out and nothi...
<p><a href="https://www.drugpatentwatch.com/blog/stop-calling-it-loss-of-exclusivity-for-most-drugs-its-loss-of-pricing-power-not-loss-of-revenue/">Source</a></p>]]></description>
		
		
		
			</item>
		<item>
		<title>The Prior Art Edge: Why Search Quality Beats Legal Firepower in Drug Patent Litigation</title>
		<link>https://www.drugpatentwatch.com/blog/the-prior-art-edge-why-search-quality-beats-legal-firepower-in-drug-patent-litigation/</link>
		
		<dc:creator><![CDATA[Insights: DrugPatentWatch - Find Your Next Blockbuster]]></dc:creator>
		<pubDate>Tue, 25 Aug 2026 09:59:09 +0000</pubDate>
				<guid isPermaLink="false">https://www.drugpatentwatch.com/blog/the-prior-art-edge-why-search-quality-beats-legal-firepower-in-drug-patent-litigation/</guid>

					<description><![CDATA[ð¨ In drug patent litigation, money talksbut search quality decides what money buys.
For years, the industry has leaned on legal firepower: big teams, aggressive briefing schedules, and the kind of motion practice that signals confidence. But the rea...
<p><a href="https://www.drugpatentwatch.com/blog/the-prior-art-edge-why-search-quality-beats-legal-firepower-in-drug-patent-litigation/">Source</a></p>]]></description>
		
		
		
			</item>
	</channel>
</rss>
